Epiomic Epidemiology Series: Myeloproliferative Neoplasms Forecast in 12 Major Markets 2017–2027

October 2017 | 39 pages | ID: E83DC1C39E6EN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Myeloproliferative Neoplasms in 12 Major Markets

Myeloproliferative neoplasms (MPNs) are a group of diseases that concern the clonal proliferation of precursors of the myeloid lineage cells in the bone marrow. MPNs are characterized by uncontrolled cell growth, and therefore can also be classified as a type of blood cancer.

This report provides the current prevalent population for three types of MPNs: polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF), across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Japan, China, India, Brazil) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, JAK2-V617F mutation status, several clinical and laboratory parameters, as well as some main symptoms and co-morbidities of the covered MPNs and features thereof have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for MPNs include:

• Thrombosis
• Splenomegaly
• Hepatomegaly
• Incident leukaemia
• Anaemia
• Portal hypertension

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global MPN market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of MPNs and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on MPN prevalent population.
• Identify sub-populations within MPNs which require treatment.
• Gain an understanding of the specific markets that have the largest number of MPN patients.

Contents

INTRODUCTION

CAUSE OF THE DISEASE

RISK FACTORS & PREVENTION

DIAGNOSIS OF THE DISEASE

VARIATION BY GEOGRAPHY/ETHNICITY

DISEASE PROGNOSIS & CLINICAL COURSE

KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE

METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS

TOP-LINE PREVALENCE FOR MYELOPROLIFERATIVE NEOPLASMS

TOP LINE PREVALENCE FOR POLYCYTHAEMIA VERA

TOP LINE PREVALENCE FOR ESSENTIAL THROMBOCYTHAEMIA

TOP LINE PREVALENCE FOR PRIMARY MYELOFIBROSIS

FEATURES OF MYELOPROLIFERATIVE NEOPLASMS PATIENTS

FEATURES OF POLYCYTHAEMIA VERA PATIENTS

FEATURES OF ESSENTIAL THROMBOCYTHAEMIA PATIENTS

FEATURES OF PRIMARY MYELOFIBROSIS PATIENTS

COMORBID CONDITIONS OF MYELOPROLIFERATIVE NEOPLASMS PATIENTS

COMORBID CONDITIONS OF POLYCYTHAEMIA VERA PATIENTS

COMORBID CONDITIONS OF ESSENTIAL THROMBOCYTHAEMIA PATIENTS

COMORBID CONDITIONS OF PRIMARY MYELOFIBROSIS PATIENTS

ABBREVIATIONS USED IN THE REPORT

OTHER BLACK SWAN ANALYSIS PUBLICATIONS

BLACK SWAN ANALYSIS ONLINE PATIENT-BASED DATABASES

PATIENT-BASED OFFERING

ONLINE PRICING DATA & PLATFORMS

REFERENCES

APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. WHO diagnostic criteria for PV, ET and PMF
Table 2. Grading of myelofibrosis
Table 3. Prevalence of Polycythaemia Vera, total (000s)
Table 4. Prevalence of Polycythaemia Vera, males (000s)
Table 5. Prevalence of Polycythaemia Vera, females (000s)
Table 6. Prevalence of Essential Thrombocythaemia, total (000s)
Table 7. Prevalence of Essential Thrombocythaemia, males (000s)
Table 8. Prevalence of Essential Thrombocythaemia, females (000s)
Table 9. Prevalence of Primary Myelofibrosis, total (000s)
Table 10. Prevalence of Primary Myelofibrosis, males (000s)
Table 11. Prevalence of Primary Myelofibrosis, females (000s)
Table 12. PV Patients with JAK2-V617F mutation, total (000s)
Table 13. PV Patients by Packed Cell Volume (L/L), total (000s)
Table 14. PV Patients on Aspirin Therapy, total (000s)
Table 15. PV Patients with Cytoreductive Drug Exposure, total (000s)
Table 16. ET Patients with JAK2-V617F mutation, total (000s)
Table 17. PMF Patients with JAK2-V617F mutation, total (000s)
Table 18. PMF Patients by IPSS Risk Category, total (000s)
Table 19. PMF Patients by Dupriez Score, total (000s)
Table 20. PMF Patients by Bone Marrow Staging, total (000s)
Table 21. PMF Patients by Haemoglobin Level (g/dL), total (000s)
Table 22. PMF Patients by White Blood Cell Count (109/dL), total (000s)
Table 23. PMF Patients by Platelet Count (109/dL), total (000s)
Table 24. PMF Patients by Circulating Blasts (%), total (000s)
Table 25. PMF Patients by Immature Granulocytes (%), total (000s)
Table 26. PMF Patients by Reticulocytes (109/dL), total (000s)
Table 27. PV Patients with Incident Thrombosis, total (000s)
Table 28. PV Patients by Incident Thrombosis Outcome, total (000s)
Table 29. PV Patients by the Presence of Prior Thrombotic Events, total (000s)
Table 30. PV Patients by the Type of Prior Thrombotic Events, total (000s)
Table 31. PV Patients by the Site of Prior Arterial Thrombotic Events, total (000s)
Table 32. PV Patients by the Site of Prior Venous Thrombotic Events, total (000s)
Table 33. PV Patients with Secondary Myelofibrosis, total (000s)
Table 34. PV Patients with Erythromelalgia, total (000s)
Table 35. PV Patients with Incident Acute Leukaemia, total (000s)
Table 36. PV Patients with Splenomegaly, total (000s)
Table 37. PV Patients with Intermittent Claudication, total (000s)
Table 38. PV Patients with Hypertension, total (000s)
Table 39. PV Patients with Chronic Heart Failure, total (000s)
Table 40. ET Patients with Incident Thrombosis, total (000s)
Table 41. ET Patients by Incident Thrombosis Outcome, total (000s)
Table 42. ET Patients by the Presence of Prior Thrombotic Events, total (000s)
Table 43. ET Patients by the Type of Prior Thrombotic Events, total (000s)
Table 44. ET Patients by the Site of Prior Arterial Thrombotic Events, total (000s)
Table 45. ET Patients by the Site of Prior Venous Thrombotic Events, total (000s)
Table 46. ET Patients with Secondary Myelofibrosis, total (000s)
Table 47. ET Patients with Incident Leukaemia, total (000s)
Table 48. ET Patients with Anaemia, total (000s)
Table 49. ET Patients with Hepatomegaly, total (000s)
Table 50. ET Patients with Splenomegaly, total (000s)
Table 51. PMF Patients with Incident Thrombosis, total (000s)
Table 52. PMF Patients by Incident Thrombosis Outcome, total (000s)
Table 53. PMF Patients by Incident Thrombosis Type, total (000s)
Table 54. PMF Patients by the Presence and Site of Prior Thrombotic Events, total (000s)
Table 55. PMF Patients with Hepatomegaly, total (000s)
Table 56. PMF Patients by the Presence and Degree of Spleen Involvement, total (000s)
Table 57. PMF Patients with Portal hypertension, total (000s)
Table 58. PMF Patients with Progression t  Acute Myelogenous Leukaemia, total (000s)
Table 59. Abbreviations and Acronyms used in the report
Table 60. USA Prevalence of Polycythaemia Vera by 5-yr age cohort, males (000s)
Table 61. USA Prevalence of Polycythaemia Vera by 5-yr age cohort, females (000s)
Table 62. Canada Prevalence of Polycythaemia Vera by 5-yr age cohort, males (000s)
Table 63. Canada Prevalence of Polycythaemia Vera by 5-yr age cohort, females (000s)
Table 64. France Prevalence of Polycythaemia Vera by 5-yr age cohort, males (000s)
Table 65. France Prevalence of Polycythaemia Vera by 5-yr age cohort, females (000s)
Table 66. Germany Prevalence of Polycythaemia Vera by 5-yr age cohort, males (000s)
Table 67. Germany Prevalence of Polycythaemia Vera by 5-yr age cohort, females (000s)
Table 68. Italy Prevalence of Polycythaemia Vera by 5-yr age cohort, males (000s)
Table 69. Italy Prevalence of Polycythaemia Vera by 5-yr age cohort, females (000s)
Table 70. Spain Prevalence of Polycythaemia Vera by 5-yr age cohort, males (000s)
Table 71. Spain Prevalence of Polycythaemia Vera by 5-yr age cohort, females (000s)
Table 72. UK Prevalence of Polycythaemia Vera by 5-yr age cohort, males (000s)
Table 73. UK Prevalence of Polycythaemia Vera by 5-yr age cohort, females (000s)
Table 74. Russia Prevalence of Polycythaemia Vera by 5-yr age cohort, males (000s)
Table 75. Russia Prevalence of Polycythaemia Vera by 5-yr age cohort, females (000s)
Table 76. Japan Prevalence of Polycythaemia Vera by 5-yr age cohort, males (000s)
Table 77. Japan Prevalence of Polycythaemia Vera by 5-yr age cohort, females (000s)
Table 78. China Prevalence of Polycythaemia Vera by 5-yr age cohort, males (000s)
Table 79. China Prevalence of Polycythaemia Vera by 5-yr age cohort, females (000s)
Table 80. India Prevalence of Polycythaemia Vera by 5-yr age cohort, males (000s)
Table 81. India Prevalence of Polycythaemia Vera by 5-yr age cohort, females (000s)
Table 82. Brazil Prevalence of Polycythaemia Vera by 5-yr age cohort, males (000s)
Table 83. Brazil Prevalence of Polycythaemia Vera by 5-yr age cohort, females (000s)
Table 84. USA Prevalence of Essential Thrombocythaemia by 5-yr age cohort, males (000s)
Table 85. USA Prevalence of Essential Thrombocythaemia by 5-yr age cohort, females (000s)
Table 86. Canada Prevalence of Essential Thrombocythaemia by 5-yr age cohort, males (000s)
Table 87. Canada Prevalence of Essential Thrombocythaemia by 5-yr age cohort, females (000s)
Table 88. France Prevalence of Essential Thrombocythaemia by 5-yr age cohort, males (000s)
Table 89. France Prevalence of Essential Thrombocythaemia by 5-yr age cohort, females (000s)
Table 90. Germany Prevalence of Essential Thrombocythaemia by 5-yr age cohort, males (000s)
Table 91. Germany Prevalence of Essential Thrombocythaemia by 5-yr age cohort, females (000s)
Table 92. Italy Prevalence of Essential Thrombocythaemia by 5-yr age cohort, males (000s)
Table 93. Italy Prevalence of Essential Thrombocythaemia by 5-yr age cohort, females (000s)
Table 94. Spain Prevalence of Essential Thrombocythaemia by 5-yr age cohort, males (000s)
Table 95. Spain Prevalence of Essential Thrombocythaemia by 5-yr age cohort, females (000s)
Table 96. UK Prevalence of Essential Thrombocythaemia by 5-yr age cohort, males (000s)
Table 97. UK Prevalence of Essential Thrombocythaemia by 5-yr age cohort, females (000s)
Table 98. Russia Prevalence of Essential Thrombocythaemia by 5-yr age cohort, males (000s)
Table 99. Russia Prevalence of Essential Thrombocythaemia by 5-yr age cohort, females (000s)
Table 100. Japan Prevalence of Essential Thrombocythaemia by 5-yr age cohort, males (000s)
Table 101. Japan Prevalence of Essential Thrombocythaemia by 5-yr age cohort, females (000s)
Table 102. China Prevalence of Essential Thrombocythaemia by 5-yr age cohort, males (000s)
Table 103. China Prevalence of Essential Thrombocythaemia by 5-yr age cohort, females (000s)
Table 104. India Prevalence of Essential Thrombocythaemia by 5-yr age cohort, males (000s)
Table 105. India Prevalence of Essential Thrombocythaemia by 5-yr age cohort, females (000s)
Table 106. Brazil Prevalence of Essential Thrombocythaemia by 5-yr age cohort, males (000s)
Table 107. Brazil Prevalence of Essential Thrombocythaemia by 5-yr age cohort, females (000s)
Table 108. USA Prevalence of Primary Myelofibrosis by 5-yr age cohort, males (000s)
Table 109. USA Prevalence of Primary Myelofibrosis by 5-yr age cohort, females (000s)
Table 110. Canada Prevalence of Primary Myelofibrosis by 5-yr age cohort, males (000s)
Table 111. Canada Prevalence of Primary Myelofibrosis by 5-yr age cohort, females (000s)
Table 112. France Prevalence of Primary Myelofibrosis by 5-yr age cohort, males (000s)
Table 113. France Prevalence of Primary Myelofibrosis by 5-yr age cohort, females (000s)
Table 114. Germany Prevalence of Primary Myelofibrosis by 5-yr age cohort, males (000s)
Table 115. Germany Prevalence of Primary Myelofibrosis by 5-yr age cohort, females (000s)
Table 116. Italy Prevalence of Primary Myelofibrosis by 5-yr age cohort, males (000s)
Table 117. Italy Prevalence of Primary Myelofibrosis by 5-yr age cohort, females (000s)
Table 118. Spain Prevalence of Primary Myelofibrosis by 5-yr age cohort, males (000s)
Table 119. Spain Prevalence of Primary Myelofibrosis by 5-yr age cohort, females (000s)
Table 120. UK Prevalence of Primary Myelofibrosis by 5-yr age cohort, males (000s)
Table 121. UK Prevalence of Primary Myelofibrosis by 5-yr age cohort, females (000s)
Table 122. Russia Prevalence of Primary Myelofibrosis by 5-yr age cohort, males (000s)
Table 123. Russia Prevalence of Primary Myelofibrosis by 5-yr age cohort, females (000s)
Table 124. Japan Prevalence of Primary Myelofibrosis by 5-yr age cohort, males (000s)
Table 125. Japan Prevalence of Primary Myelofibrosis by 5-yr age cohort, females (000s)
Table 126. China Prevalence of Primary Myelofibrosis by 5-yr age cohort, males (000s)
Table 127. China Prevalence of Primary Myelofibrosis by 5-yr age cohort, females (000s)
Table 128. India Prevalence of Primary Myelofibrosis by 5-yr age cohort, males (000s)
Table 129. India Prevalence of Primary Myelofibrosis by 5-yr age cohort, females (000s)
Table 130. Brazil Prevalence of Primary Myelofibrosis by 5-yr age cohort, males (000s)
Table 131. Brazil Prevalence of Primary Myelofibrosis by 5-yr age cohort, females (000s)